EZH2 inhibitors up-regulate the permeability of immune cells in tumor microenvironment and induce reprogramming of immunosuppressive cells, thus enhancing the killing effect of PARP inhibitors on tumor cells. This evidence concerns the gene PARP1 and neoplasm.